Kamada Reports Positive Phase II Data with Inhaled AAT in Cystic Fibrosis
The Results Demonstrate the Product Has an Excellent Safety Profile and Shows Promising Signs of Efficacy, as Indicated by a Reduction in Lung Inflammation
14-Oct-2008 -
Kamada announced positive data from its Phase II study evaluating inhaled Alpha-1 Antitrypsin (AAT) delivered via an Investigational eFlow® Nebulizer System (PARI Pharma GmbH), in the treatment of cystic fibrosis. The results demonstrate the product has an excellent safety profile and shows ...
clinical trials
cystic fibrosis
inflammation
+3